TALIMOGENE LAHERPAREPVEC ENHANCES THE EFFICACY OF PD-1 BLOCKADE

被引：0
|
作者：
Ribas, A.
Dummer, R.
Puzanov, I
VanderWalde, A.
Andtbacka, R. H.
Michielin, O.
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1211 / 1211
页数：1
相关论文
共 50 条
  • [41] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Shogo Kumagai
    Yosuke Togashi
    Takahiro Kamada
    Eri Sugiyama
    Hitomi Nishinakamura
    Yoshiko Takeuchi
    Kochin Vitaly
    Kota Itahashi
    Yuka Maeda
    Shigeyuki Matsui
    Takuma Shibahara
    Yasuho Yamashita
    Takuma Irie
    Ayaka Tsuge
    Shota Fukuoka
    Akihito Kawazoe
    Hibiki Udagawa
    Keisuke Kirita
    Keiju Aokage
    Genichiro Ishii
    Takeshi Kuwata
    Kenta Nakama
    Masahito Kawazu
    Toshihide Ueno
    Naoya Yamazaki
    Koichi Goto
    Masahiro Tsuboi
    Hiroyuki Mano
    Toshihiko Doi
    Kohei Shitara
    Hiroyoshi Nishikawa
    [J]. Nature Immunology, 2020, 21 : 1346 - 1358
  • [42] PD-1 blockade works alone
    [J]. Nature Biotechnology, 2022, 40 : 986 - 986
  • [43] PD-1 BLOCKADE IN CANCER IMMUNOTHERAPY
    Srivastava, N.
    Avigan, D.
    Rosenblatt, J.
    [J]. DRUGS OF THE FUTURE, 2014, 39 (02) : 129 - 132
  • [44] NEOADJUVANT PD-1 BLOCKADE IN NSCLC
    Killock, David
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (07) : 404 - 404
  • [45] Neoadjuvant PD-1 blockade in NSCLC
    David Killock
    [J]. Nature Reviews Clinical Oncology, 2018, 15 : 404 - 404
  • [46] PD-1 Blockade for Solid Tumors
    不详
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (04) : 568 - 568
  • [47] Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety
    Raman, Steven S.
    Hecht, Joel Randolph
    Chan, Emily
    [J]. IMMUNOTHERAPY, 2019, 11 (08) : 705 - 723
  • [48] The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
    Kumagai, Shogo
    Togashi, Yosuke
    Kamada, Takahiro
    Sugiyama, Eri
    Nishinakamura, Hitomi
    Takeuchi, Yoshiko
    Vitaly, Kochin
    Itahashi, Kota
    Maeda, Yuka
    Matsui, Shigeyuki
    Shibahara, Takuma
    Yamashita, Yasuho
    Irie, Takuma
    Tsuge, Ayaka
    Fukuoka, Shota
    Kawazoe, Akihito
    Udagawa, Hibiki
    Kirita, Keisuke
    Aokage, Keiju
    Ishii, Genichiro
    Kuwata, Takeshi
    Nakama, Kenta
    Kawazu, Masahito
    Ueno, Toshihide
    Yamazaki, Naoya
    Goto, Koichi
    Tsuboi, Masahiro
    Mano, Hiroyuki
    Doi, Toshihiko
    Shitara, Kohei
    Nishikawa, Hiroyoshi
    [J]. NATURE IMMUNOLOGY, 2020, 21 (11) : 1346 - +
  • [49] Combination Immunotherapy with 4-1BB Activation and PD-1 Blockade Enhances Antitumor Efficacy in a Mouse Model of Subcutaneous Tumor
    Shindo, Yoshitaro
    Yoshimura, Kiyoshi
    Kuramasu, Atsuo
    Watanabe, Yusaku
    Ito, Hideaki
    Kondo, Tomoko
    Oga, Atsunori
    Ito, Hiroshi
    Yoshino, Shigefumi
    Hazama, Shoichi
    Tamada, Koji
    Yagita, Hideo
    Oka, Masaaki
    [J]. ANTICANCER RESEARCH, 2015, 35 (01) : 129 - 136
  • [50] Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model
    Reardon, David A.
    Gokhale, Prafulla C.
    Klein, Sarah R.
    Jones, Kristen L.
    Kirschmeier, Paul T.
    Speranza, Maria
    Koblish, Holly
    Scherle, Peggy
    Leopold, Lance
    Newton, Robert
    Freeman, Gordon J.
    [J]. CANCER RESEARCH, 2017, 77
12345